Is bipolar disorder a mitochondrial disease?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
While we continue to refine our understanding of the pathophysiology of bipolar disorder (BD), a considerable distance remains before we establish a complete picture of the relevant processes and pathways that result in this illness. Recently, there has been a major focus on the neuroprotective effects of mood stabilizers and, hence, the cell loss and damage in specific brain regions in patients with BD.1,2 This raises the question, what leads to the increasingly well-described pattern of neuronal damage and loss in this disease? Impairment of mitochondrial energy metabolism, one mechanism that is clearly important in many diseases of the brain, has recently become compellingly implicated in BD.3 The evidence to support this mechanism comes from studies using diverse approaches. These data are briefly outlined below. Both structural and functional MRI (fMRI) studies have identified specific brain regions in BD patients, namely, the prefrontal cortex and limbic regions, which appear to be altered in size and their function impaired.4 fMRI studies have also revealed decreased pH, phosphocreatine and adenosine triphophate (ATP) levels and increased lactate levels in these brain regions, all of which are hallmarks of decreased energy metabolism.5 Although these data do not specifically implicate mitochrondria, they clearly suggest energy imbalance in these brain regions. In a series of elegant experiments, Kato and Kato6 identified abnormalities in mitochondrial DNA in patients with BD and further elaborated the contribution of several amino acid substitutions in specific candidate genes in several patient samples. Further, studies on gene coding for components of the electron transport chain are found both in mitochondrial and nuclear DNA, and significant associations with BD, including a gene on chromosome 18p11, which is a well-replicated chromosomal region in linkage studies of patients with BD, have been reported.6 Studies using DNA microarray techniques have demonstrated a remarkable concordance across several laboratories, with different patient samples identifying decreased expression of a cluster of genes in components of the mitochondrial electron transport chain in BD.7–9 This technique, which is not limited by a specific hypothesis based on previous findings, allowed investigators to entertain novel ideas. The remarkable consistency between the results of these microarray studies is encouraging. Notwithstanding concerns that at least some of these changes relate to lower brain pH in at least some of the brain tissue samples that arise from differences in antemortem agonal factors, postmortem delay and storage of postmortem brain, that the mitochondrial abnormalities are remarkably evident in patients with BD, compared to other psychiatric disorders.7 Since our laboratory reported some of these findings, I may be somewhat biased about the relevance of these findings. Evidence from animal studies and cellular models on the molecular pharmacology of mood stabilizing drugs has also implicated mitochondrial energy metabolism as a target for these drugs. An earlier series of investigations showed that lithium and other mood stabilizers increased the expression of the antiapoptosis gene Bcl-2.2 These were among the first studies to demonstrate a mitochondrial target for mood stabilizers. DNA microarray studies in animals examining targets of mood stabilizers, at least lithium and valproate, strongly suggested that these drugs increase energy metabolism and decrease oxidative damage and that these effects may be important for their efficacy in BD.10 For instance, our laboratory has shown that the level and activity of glutathione, the major defence against oxidative damage in the brain and the activity of its metabolic enzymes, are increased by treatment with several mood stabilizers, thus enhances the brain's response to the insults that may occur in BD that involve altered energy metabolism.10 Most of this evidence comes from the administration of mood stabilizers to animals under normal laboratory conditions. However, some of the most recent studies demonstrate that such effects are also observed under pathological conditions such as excitotoxicity and after oxidative stress.11 The targets for these drugs are not identical to the markers found in patient samples. However, they suggest complimentary mechanisms that could prevent or compensate for the defects found in patients. For instance, enhancing glutathione defence could decrease potential oxidative damage resulting from mitochondrial defects or mutations in the electron transport chain. Mitochondrial dysfunction has been long studied in other brain diseases, including neurodegenerative diseases and, to some extent, schizophrenia.12,13 Several brain illnesses result from mutations in mitochondrial DNA, such as mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), among others.14 Fatal Leigh syndrome result
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Puccio, H., Simon, D., Cossée, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P., & Koenig, M. (2001) · Nature Genetics · doi:10.1038/84818 · Cited by 738
Schizophrenia and Oxidative Stress: Glutamate Cysteine Ligase Modifier as a Susceptibility Gene
Tosic, M., Ott, J., Barral, S., Bovet, P., Deppen, P., Gheorghita, F., Matthey, M.-L., Parnas, J., Preisig, M., Saraga, M., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/507566 · Cited by 234
Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate
Cui, J., Shao, L., Young, L. T., & Wang, J.-F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.010 · Cited by 160
Self-citation
Cited by
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
“Impaired mitochondrial energy metabolism has also been suggested to be a fundamental defect in bipolar disorder (Kato, 2007; Young, 2007), with hypometabolism, energy imbalance and oxidative stress assuming secondary roles, and may present an alternative hypothesis.”
BackgroundBipolar disorder diagnosis: challenges and future directions
Phillips, M. L., & Kupfer, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60989-7 · Cited by 665
The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode
Selek, S., Savas, H. A., Gergerlioglu, H. S., Bulbul, F., Uz, E., & Yumru, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.08.006 · Cited by 172
Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: a systematic review
Rucklidge, J. J., & Kaplan, B. J. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.143 · Cited by 116
Otte, D.-M., Sommersberg, B., Kudin, A., Guerrero, C., Albayram, Ö., Filiou, M. D., Frisch, P., Yilmaz, Ö., Drews, E., Turck, C. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.109 · Cited by 97
Metadata
- Authors
- Young, L. T.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2007-05
- Volume
- 32
- Issue
- 3
- Pages
- 160-161
- ISSN
- 1180-4882 (ISSN-L)
- 1488-2434
- OpenAlex
- W2170288106
- Cited by
- 50
- References
- 3
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is bipolar disorder a mitochondrial disease? https://app.cochat.ai/papers/10.1139/jpn.0715
- The paper
- Young, L. T. (2007). Is bipolar disorder a mitochondrial disease? Journal of Psychiatry and Neuroscience. https://doi.org/10.1139/jpn.0715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.